Approval · Notice of Compliance 29768 · 2022
SIMBRINZA: Notice of Compliance 29768
Issued December 23, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29768
- Date
- December 23, 2022
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the product monograph and conversion of the product monograph to the Master Template format
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SIMBRINZA | Not yet assigned | — |
Medicinal ingredients
- BRIMONIDINE TARTRATE 0.2 PER
- BRINZOLAMIDE 1 PER